People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental health conditions. However, they may cover the FDA-approved nasal spray ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for treatment-resistant depression. According to reports, the FDA approved ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment ... them that the treatments work,” Merrill said. “Ketamine is a safe medication when used under appropriate ...

A nasal spray derived from ketamine gets federal clearance to help some people treat depression. The Federal Drug Administration approved "Spravato" from Johnson and Johnson, to be used by people ...

Ketamine-assisted psychotherapy (KAP) uses low doses of ketamine alongside psychotherapy to treat mental health conditions.